Please login to the form below

Not currently logged in
Email:
Password:

Lucid wins med ed consultancy of the year

Second victory in a row at Communiqué Awards
Lucid at the Communique Awards 2014

Lucid was named Medical Education Consultancy of the Year for the second year in a row at last night's Communiqué Awards.

The agency's achievements during 2013 included 100 per cent retention of its client roster from 2012 as well as an additional nine new clients and 16 new recruits.

Judges described Lucid as “an agency to make you jealous”, adding: “Lucid is doing really well and nailing it.”

Other comments included: “It's great to see that they are using learnings from client work to develop the team. Lucid is slick, poised and prepared!”

Jan Steele, operations director at Lucid commented that the award was “the award we wanted”.

She added: “To be recognised, for the second year running, for our unique and passionate approach to medical education is fantastic. I am so proud of our work and our fabulous team.”

Other finalists in the category include Litmus MME, Virgo Health Education and Watermeadow Medical (part of Ashfield Healthcare Communications).

Lucid also picked up the award for Excellence in Professional Education Programmes for its Arena for Immunology project for AbbVie. This project also helped Lucid to a highly commended in the Excellence in Communications via Meetings category.

The Communiqué Awards are run by PMLiVE publishers PMGroup and the awards ceremony took place at London's Grosvenor House Hotel, Park Lane, on July 3, 2014.

See the full results of the Communiqué Awards 2014
See photos of the winners from the Communiqué Awards 2014

Article by
Thomas Meek

4th July 2014

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...